#Taiwan #Taipei #HanchorBio #HCB101 #HCB301

HanchorBio's Groundbreaking Advances in Immunotherapy

HanchorBio Inc., a leading biotechnology firm at the forefront of immunotherapy development, is set to present key findings on its advanced therapies, HCB101 and HCB301, at five pivotal oncology congresses in the fourth quarter of 2025. This ambitious plan highlights HanchorBio's commitment to revolutionizing cancer treatment through innovative approaches.

Pioneering Clinical Data Presentation

The presentations will feature vital clinical data on HCB101, an engineered SIRPα-Fc fusion protein, alongside preclinical insights on HCB301, a tri-specific checkpoint immunotherapy. This underscores HanchorBio's dedication to addressing the challenges of cancer therapies by continuously enhancing its product pipeline.

The major congresses scheduled for late 2025 include:

• - Federation of Asian Clinical Oncology (FACO): This event will occur from October 24-25, where the company will unveil two poster presentations regarding the HCB101 monotherapy and its combination with standard care treatments targeting advanced cancers.
• - Society for Immunotherapy of Cancer (SITC): Running from November 5-9, HCB101 will feature prominently with two late-breaking poster presentations. These will focus on safety, pharmacology, and emerging efficacy signals, compounded by a presentation of the first preclinical data for HCB301.
• - ESMO Asia Congress: Scheduled for December 5-7, this congress will present updated results from the HCB101-101 study, showcasing its safety and effectiveness across various solid tumors and hematologic malignancies.
• - American Society of Hematology (ASH) Annual Meeting: From December 6-9, HanchorBio will share insights from the first-in-human Phase 1 study of HCB101 for patients with relapsed/refractory non-Hodgkin lymphoma.
• - ESMO Immuno-Oncology Congress (ESMO-IO): Running from December 10-12, this event will integrate data from the HCB101 monotherapy and combination studies across several solid tumor indications.

Highlights of HCB101 and HCB301 Research

HCB101 - A Differentiated CD47-SIRPα Blockade

HCB101 is a next-generation immunotherapy characterized by:

• - Its unique design as a 3.5th-generation affinity-optimized SIRPα-Fc fusion protein, using HanchorBio's proprietary FBDB™ platform, which minimizes binding to red blood cells to reduce the risk of anemia.
• - The ability to maintain high levels of antibody-dependent cellular phagocytosis (ADCP), effectively bridging innate and adaptive immune responses.

Key advantages include robust safety and enhanced immune activation, with early signs of tumor control in clinical settings indicating its potential effectiveness.

HCB301 - Tri-Specific Checkpoint Immunotherapy

HCB301 integrates three synergistic immune mechanisms into one targeted therapy. This innovative approach combines:

• - CD47-SIRPα blockade to activate macrophage-mediated phagocytosis.
• - PD-1 inhibition, aimed at restoring functionality to exhausted T cells.
• - TGF-b pathway suppression to improve the tumor microenvironment.

Preclinical studies have showcased HCB301’s potent anti-tumor activities and enhanced immune activation. The forthcoming results at SITC 2025 will further illuminate its capabilities and potential.

Commitment to Innovative Therapies

Scott Liu, Chairman and CEO of HanchorBio, emphasized the significance of these presentations, stating, "Demonstrating progress across numerous key oncology meetings within a quarter showcases the rapid advancement of HCB101. Coupled with the emerging data from HCB301, our innovations illustrate a firm commitment to transforming treatments for patients grappling with challenging cancers."

HanchorBio is strategically located across Taipei, Shanghai, and San Francisco Bay Area, propelling its focus on developing superior immunotherapies with a promise of addressing unmet medical needs in oncology.

Through HanchorBio’s advanced FBDB™ platform, the company continues to push boundaries, seeking to innovate cancer treatments that can remarkably reshape patient outcomes.

For more insights about HanchorBio’s ongoing research and developments, please visit www.HanchorBio.com.